← Back to Search

Taldefgrobep Alfa for Spinal Muscular Atrophy (RESILIENT Trial)

Phase 3
Waitlist Available
Research Sponsored by Biohaven Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ambulant or Non-Ambulant
Spinal Muscular Atrophy confirmed by genetic diagnosis of 5q-autosomal recessive SMA as well as SMN2 copy number
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 48
Awards & highlights

RESILIENT Trial Summary

This trial will study if adding taldefgrobep alfa to current treatments for spinal muscular atrophy (SMA) is effective and safe.

Who is the study for?
This trial is for people with Spinal Muscular Atrophy who are already on a stable dose of specific SMA treatments like nusinersen or risdiplam, or have had gene therapy. Participants must weigh at least 15kg and can be ambulant or non-ambulant. Those needing daytime ventilation, recent spinal fusion patients, and those with certain implants or previous anti-myostatin therapies cannot join.Check my eligibility
What is being tested?
The study tests taldefgrobep alfa's effectiveness and safety as an additional treatment for Spinal Muscular Atrophy alongside existing medications compared to a placebo. It aims to see if adding taldefgrobep alfa improves patient outcomes.See study design
What are the potential side effects?
While the side effects of taldefgrobep alfa aren't specified here, similar drugs may cause injection site reactions, muscle pain, headaches, nausea, and potential allergic reactions.

RESILIENT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can walk with or without assistance.
Select...
I have been genetically diagnosed with Spinal Muscular Atrophy.
Select...
I am currently on a stable dose of SMA treatment and plan to stay on it.

RESILIENT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 48
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 48 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Efficacy of taldefgrobep alfa compared to placebo in change in the 32 item Motor Function Measure (MFM-32) total score

RESILIENT Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: taldefgrobep alfaExperimental Treatment1 Intervention
taldefgrobep alfa - Double-blind (DB) Phase: Participants receive weight based 35 mg/50 mg weekly subcutaneous injection for 48-week DB phase. taldefgrobep alfa/taldefgrobep alfa - Extension Phase: Participants receive weight based 35 mg/50 mg weekly subcutaneous injection for 48-week Open label Extension (OLE) phase.
Group II: PlaceboPlacebo Group2 Interventions
Placebo - Double-blind (DB) Phase: Participants receive weight based 35 mg/50 mg weekly subcutaneous injection for 48-week DB phase. Placebo/taldefgrobep alfa - Extension Phase: Participants who receive placebo during DB phase, receive weight based 35 mg/50 mg weekly subcutaneous taldefgrobep alfa injection for 48-week OLE phase.

Find a Location

Who is running the clinical trial?

Biohaven Pharmaceuticals, Inc.Lead Sponsor
47 Previous Clinical Trials
36,866 Total Patients Enrolled
Lindsey Lair, MDStudy DirectorBiohaven Pharmaceuticals, Inc.

Media Library

taldefgrobep alfa Clinical Trial Eligibility Overview. Trial Name: NCT05337553 — Phase 3
Spinal Muscular Atrophy Research Study Groups: taldefgrobep alfa, Placebo
Spinal Muscular Atrophy Clinical Trial 2023: taldefgrobep alfa Highlights & Side Effects. Trial Name: NCT05337553 — Phase 3
taldefgrobep alfa 2023 Treatment Timeline for Medical Study. Trial Name: NCT05337553 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Will this experimental treatment be available to those who are elderly?

"Children and adolescents aged 4-21 may be eligible for this clinical trial. There are currently 63 similar studies for those under 18 and 173 for senior citizens."

Answered by AI

What is the mortality rate of tadefgrobep alfa?

"While Phase 3 trials are not as well established as Phase 4 trials, there is still some supporting data for efficacy and safety. Therefore, our team has given tadefgrobep alfa a safety score of 3."

Answered by AI

What are the entrance requirements for this research project?

"This trial is open to 225 people with Oppenheim Disease who are between the ages of 4 and 21. Applicants must meet the following criteria: Ambulant or Non-Ambulant, Spinal muscular atrophy confirmed by genetic diagnosis of 5q-autosomal recessive SMA as well as SMN2 copy number, Treated with an SMA disease-modifying therapy and anticipated to remain on that same treatment regimen and dose throughout the trial including nusinersen, risdiplam, and/or a history of onasemnogene abeparvovec, Key."

Answered by AI

Could you please give me the number of medical facilities where this research is being conducted?

"There are a total of 34 locations hosting this clinical trial, with children's hospitals in Phoenix, Gainesville, and Chicago participating."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
Rare Disease Research
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
2022. "A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05337553.
All > Spinal Muscular Atrophy
~74 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top